---
figid: PMC4334449__nihms656347f1
figlink: /pmc/articles/PMC4334449/figure/F1/
number: F1
caption: 'Pathogenesis of HCC and targets for chemopreventive agents. Receptor tyrosine
  kinase pathways induce MAPK and PI3K–Akt kinase signalling pathways in >50% of HCCs.
  Activation of the PI3K–Akt kinase signalling pathway results in disruption of the
  mTOR pathway, which is seen in 40–50% of cases of HCC, leading to inactivation of
  tumour suppressors such as PTEN, and promoting carcinogenesis. Statins prevent post-translational
  prenylation of signalling Ras/ Raf proteins, inhibit the activation of the proteasome
  pathway, limiting the degradation of the cyclin-dependent kinase inhibitors p21
  and p27, and block Myc phosphorylation and activation, suppressing tumour initiation
  and growth. Metformin activates AMPK, which inhibits the mTOR pathway. Thiazolidinediones
  also exert anticancer effects through inhibition of the ubiquitin-proteasome system
  and extracellular signal-regulated kinase pathway. Antiplatelet agents, such as
  aspirin, decrease T-cell-mediated inflammation through inhibition of cyclo-oxygenase-2,
  decreasing severity of fibrosis and progression to HCC. Insulin and sulphonylureas
  might promote hepatocarcinogenesis by increasing IGFR1 activity, resulting in abnormal
  stimulation of multiple cellular signalling cascades, enhancing growth-factor-dependent
  cell proliferation and affecting cell metabolism. Cirrhotic-stage HCV and HBV infection
  leaves the liver prone to the development of activating mutations in oncogenes and
  inactivating genetic and epigenetic suppression of tumour suppressor genes. Abbreviations:
  AMPK, adenosine monophosphate-activated protein kinase; HCC, hepatocellular carcinoma;
  IGFR1, insulin-like growth factor receptor 1; IR, insulin receptor; MAPK, Ras mitogen-activated
  protein kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
  3-kinase; PPAR-γ, peroxisome proliferator activated receptor γ.'
pmcid: PMC4334449
papertitle: Chemopreventive strategies in hepatocellular carcinoma.
reftext: Siddharth Singh, et al. Nat Rev Gastroenterol Hepatol. ;11(1):45-54.
pmc_ranked_result_index: '69679'
pathway_score: 0.9669132
filename: nihms656347f1.jpg
figtitle: Pathogenesis of HCC and targets for chemopreventive agents
year: ''
organisms:
- Homo sapiens
ndex: 74b64405-decf-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4334449__nihms656347f1.html
  '@type': Dataset
  description: 'Pathogenesis of HCC and targets for chemopreventive agents. Receptor
    tyrosine kinase pathways induce MAPK and PI3K–Akt kinase signalling pathways in
    >50% of HCCs. Activation of the PI3K–Akt kinase signalling pathway results in
    disruption of the mTOR pathway, which is seen in 40–50% of cases of HCC, leading
    to inactivation of tumour suppressors such as PTEN, and promoting carcinogenesis.
    Statins prevent post-translational prenylation of signalling Ras/ Raf proteins,
    inhibit the activation of the proteasome pathway, limiting the degradation of
    the cyclin-dependent kinase inhibitors p21 and p27, and block Myc phosphorylation
    and activation, suppressing tumour initiation and growth. Metformin activates
    AMPK, which inhibits the mTOR pathway. Thiazolidinediones also exert anticancer
    effects through inhibition of the ubiquitin-proteasome system and extracellular
    signal-regulated kinase pathway. Antiplatelet agents, such as aspirin, decrease
    T-cell-mediated inflammation through inhibition of cyclo-oxygenase-2, decreasing
    severity of fibrosis and progression to HCC. Insulin and sulphonylureas might
    promote hepatocarcinogenesis by increasing IGFR1 activity, resulting in abnormal
    stimulation of multiple cellular signalling cascades, enhancing growth-factor-dependent
    cell proliferation and affecting cell metabolism. Cirrhotic-stage HCV and HBV
    infection leaves the liver prone to the development of activating mutations in
    oncogenes and inactivating genetic and epigenetic suppression of tumour suppressor
    genes. Abbreviations: AMPK, adenosine monophosphate-activated protein kinase;
    HCC, hepatocellular carcinoma; IGFR1, insulin-like growth factor receptor 1; IR,
    insulin receptor; MAPK, Ras mitogen-activated protein kinase; mTOR, mammalian
    target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PPAR-γ, peroxisome proliferator
    activated receptor γ.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKAG3
  - PRKAG2
  - MYC
  - FLT4
  - KDR
  - PRKAA1
  - AKT2
  - PTEN
  - PIK3CD
  - PRKAA2
  - RAF1
  - BRAF
  - HRAS
  - ARAF
  - PDGFRA
  - CCND1
  - CCND2
  - TP53
  - AKT3
  - AKT1
  - MAPK1
  - MAPK3
  - STK11
  - MDM2
  - MAP2K1
  - MAP2K2
  - KRAS
  - NRAS
  - FLT1
  - PRKAG1
  - CDK2
  - CCND3
  - EGFR
  - PIK3CA
  - PIK3CB
  - MTOR
  - PIK3CG
  - PIK3R3
  - PDGFRB
  - PIK3R6
  - PRKAB1
  - PRKAB2
  - PIK3R5
  - PIK3R4
  - Aspirin
  - Metformin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: Myc
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND2
  entrez: '894'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: CDK2
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CyclinD
  symbol: Cyclin_D
  source: bioentities_symbol
  hgnc_symbol: CCND3
  entrez: '896'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
chemicals:
- word: Aspirin
  source: MESH
  identifier: D001241
- word: Metformin
  source: MESH
  identifier: D008687
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4334449__F1
redirect_from: /figures/PMC4334449__F1
figtype: Figure
---
